EGS Beteiligungen
VC Fund
Zürich, Switzerland
EGS Beteiligungen is a VC fund in Zürich focused on Health Care and Sports. EGS Beteiligungen invests in Swiss companies and actively contributes to the sustainable, positive development of those companies.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries EGS Beteiligungen invests in
Stages EGS Beteiligungen invests in
Countries EGS Beteiligungen invests in
Investment Focus
Industry
- Health Care 2 (33%)
- Sports 1 (17%)
- Medical 1 (17%)
- Software 1 (17%)
- Automotive 1 (17%)
Stage
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
- Funding Round 1 (17%)
- Secondary Market 1 (17%)
Country
- Switzerland 3 (50%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oviva
|
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $233.7M / Series D / Jan 22, 2026 | |
|
Oviva
|
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | Secondary Market / Jan 22, 2026 | |
Delvitech
|
Delvitech designs, produces and supplies intelligent solutions for automatic optical inspection (AOI)cfor the electronics industry.Delvitech supplies replacement parts, maintenance services and software updates for AOI Trion, Vantage and Symbion. | $40M / Series B / Nov 11, 2025 | |
Bcomp
|
Bcomp is a Fribourg-based startup that specializes in natural fiber composites.Bcomp has developed and patented technologies allowing the fabrication of structural parts from natural fibres. The company's IP is composed of a patent and several years of developments of specific processing technologies derived from the aerospace or marineindustry. While increasing and consolidating our R&D efforts through a network of academic partners, the company develop products in close collaboration with the company'scustomers to account for their specific needs. | $39.4M / Series C / Apr 16, 2024 | |
spineart
|
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of MinimallyInvasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment.Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital. | $31.3M | |
|
spineart
|
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.Spineart is a pioneer in its field, having introduced unique patented and clinically validated technologies in the fields of MinimallyInvasive Surgery, Motion Preservation, Fusion, Biologics, and Fractures Treatment.Spineart markets a complete portfolio combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital. | $31.3M |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does EGS Beteiligungen invest in?
EGS Beteiligungen invests primarily in Health Care, Sports and Medical startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did EGS Beteiligungen last invest?
The most recent investment recorded for EGS Beteiligungen closed in Jan 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
